Sugar-Sweetened Drinks Linked to Increased Incidence of Liver Cancer, Mortality
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 8, 2023 -- Intake of sugar-sweetened beverages is associated with an increased incidence of liver cancer and death from chronic liver disease among postmenopausal women, according to a study published in the Aug. 8 issue of the Journal of the American Medical Association.
Longgang Zhao, Ph.D., from the University of South Carolina in Columbia, and colleagues conducted a prospective cohort study involving 98,786 postmenopausal women aged 50 to 79 years enrolled at 40 clinical centers in the United States to examine the associations of intake of sugar-sweetened beverages and artificially sweetened beverages with the incidence of liver cancer and chronic liver disease mortality.
A total of 207 women developed liver cancer and 148 died from chronic liver disease during a median follow-up of 20.9 years. The researchers found that 6.8 and 13.1 percent of women consumed one or more sugar-sweetened and artificially sweetened beverage servings per day, respectively, at three-year follow-up. Those who consumed one or more servings per day of sugar-sweetened beverages had a significantly higher risk for liver cancer and chronic liver disease mortality than those with intake of three or fewer servings of sugar-sweetened beverages per month. No significantly increased incidence of liver cancer or chronic liver disease mortality was seen for those who consumed one or more artificially sweetened beverages per day compared with intake of three or fewer per month.
"Future studies should confirm these findings and identify the biological pathways of these associations," the authors write.
One author disclosed financial ties to Mars Edge.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer
MONDAY, Jan. 29, 2024 -- For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial...
Direct-Acting Antivirals Still Underused in Hep C-Related Liver Cancer
TUESDAY, Nov. 21, 2023 -- Direct-acting antiviral agents (DAAs) remain underutilized in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), according to...
Increasing Generational Status Linked to Elevated Risk for Liver Cancer
MONDAY, Nov. 20, 2023 -- For Mexican Americans, increasing generational status is associated with an increased risk for hepatocellular carcinoma (HCC), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.